Johnson & Johnson’s Rybrevant Faspro won accelerated FDA approval for patients with advanced head and neck cancer that has progressed after prior chemotherapy and immunotherapy. The bispecific antibody expands on the drug’s earlier use in certain lung cancers. The approval targets a difficult-to-treat setting where response durability is still typically a key question under accelerated pathways. J&J will be expected to generate confirmatory evidence as the program progresses. For biotech and pharma, the move reinforces the continuing regulatory appetite for bispecifics in oncology when response signals are compelling, and it adds another checkpoint for developers aiming to convert accelerated findings into durable approvals.